Notice of Annual General Meeting

Paris, France and Camberley, UK – 13 May 2022 – Novacyt S.A. (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that the Company’s Annual General Meeting (“AGM”) will be held at 2pm CEST/1pm BST on 21 June 2022 as an open virtual meeting. Further details of the AGM will be provided

Visit Page

Full year 2021 results and update on growth strategy

Full year revenue and EBITDA in line with market expectations despite challenging and changing COVID-19 testing marketLeveraging core capabilities to become a leading, global clinical diagnostics company targeting annual revenues in excess of £100m in five years http://novacyt.com/wp-content/uploads/2022/04/Novacyt-Full-year-2021-results-and-update-on-growth-strategy.pdf

Visit Page

DHSC dispute update

Paris, France and Camberley, UK – 26 April 2022 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces an update on its ongoing dispute with the Department of Health and Social Care (“DHSC”). http://novacyt.com/wp-content/uploads/2022/04/Novacyt-DHSC-dispute-update-1.pdf

Visit Page

Notice of Full Year 2021 Results and Investor Presentation

Paris, France and Camberley, UK – 20 April 2022 – Novacyt S.A. (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that it will report its audited financial results for the year ended 31 December 2021 on Thursday, 28 April 2022. http://novacyt.com/wp-content/uploads/2022/04/Notice-of-FY21-Results-.pdf

Visit Page

Approval of second direct-to-PCR COVID-19 test in the UK under CTDA legislation

Paris, France and Camberley, UK – 12 April 2022 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that the Company’s PROmate® COVID-19 1G (q32) Real-Time PCR test has been approved in the UK under the UK Health Security Agency’s Medical Devices (Coronavirus Test Device Approvals) (Amendment) Regulations 2021 (“CTDA”).

Visit Page

Director/PDMR Shareholding

Paris, France and Camberley, UK – 25 March 2022 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that it has been notified that, on 25 March 2022, the following Director purchased ordinary shares of €1/15 each in the Company (the “Ordinary Shares”): http://novacyt.com/wp-content/uploads/2022/03/3.-Novacyt-Director-Dealings-DA-ENG.pdf

Visit Page

Director/PCA Dealing

Paris, France and Camberley, UK – 18 March 2022 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that it was notified on 18 March 2022 that Jean-Pierre Crinelli, a Non-Executive Director of Novacyt, acquired 3,208 ordinary shares in the Company at a price of €2.41 per share. Following the

Visit Page

Director/PDMR Shareholding

Paris, France and Camberley, UK – 15 March 2022 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that it has been notified that, on 14 March 2022, the following Director purchased ordinary shares of €1/15 each in the Company (the “Ordinary Shares”): http://novacyt.com/wp-content/uploads/2022/03/Novacyt-Director-Dealings-15.03.2022.pdf

Visit Page

Holdings in Company

Paris, France and Camberley, UK – 11 March 2022 – Novacyt S.A. (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that it was notified by Biosynex SA (“Biosynex”) on 10 March 2022 that, as at 7 march 2022, Biosynex’s holding in the Company on a voting and capital basis is 5.54% (3,915,350

Visit Page

Holdings in Company

Paris, France and Camberley, UK – 18 February 2022 – Novacyt S.A. (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that it was notified by Biosynex SA (“Biosynex”) on 18 February 2022 that, as at 14 February 2022, Biosynex’s holding in the Company on a voting and capital basis is 4.04%

Visit Page